

Claims

1. A combination of (i) a FLT3-inhibitor and (ii) SEL24/MEN1703 for use as medicament.
- 5 2. The combination according to claim 1, wherein the FLT3-inhibitor is selected from the group consisting of Gilteritinib, Quizartinib, Midostaurin, and combinations thereof.
3. Use of (i) a FLT3-inhibitor and (ii) SEL24/MEN1703 in the manufacture of a medicament for combination therapy to treat a patient suffering from cancer.
- 10 4. Use of (i) a FLT3-inhibitor in the manufacture of a first medicament and use of (ii) SEL24/MEN1703 in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat a patient suffering from cancer.
- 15 5. Use of (i) a FLT3-inhibitor in the manufacture of a medicament for use in combinatorial therapy for treating a patient suffering from cancer, wherein said medicament is to be administered in combination with (ii) SEL24/MEN1703.
- 20 6. The use according to any one of claims 3 to 5, wherein the cancer is a hematological cancer.
7. The use according to any one of claims 3 to 6, wherein the cancer is acute myeloid leukemia (AML).
- 25 8. The use according to any one of the preceding claims, wherein SEL24/MEN1703 is to be administered at a daily dose of 50 mg to 150 mg.
9. The use according to any one of claims 3 to 8, wherein Gilteritinib is to be administered at a daily dose of 40 mg to 400 mg.
- 30 10. The use according to any one of claims 3 to 9, wherein Quizartinib is to be administered at a daily dose of 10 mg to 50 mg.
- 35 11. The use according to any one of claims 3 to 10, wherein Midostaurin is to be administered at a daily dose of 20 mg to 80 mg.
12. The use according to any one of the preceding claims, wherein (i) and (ii) are to be administered as separate dosage forms.
- 40 13. The use according to any one of the preceding claims, wherein (i) and (ii) are to be administered orally.
- 45 14. A kit of dosage forms comprising (i) a dosage form comprising a FLT3-inhibitor and (ii) a dosage form comprising SEL24/MEN1703.

15. The kit according to claim 14, wherein the FLT3-inhibitor is selected from the group consisting of Gilteritinib, Quizartinib, Midostaurin, and combinations thereof.

16. A dosage form comprising (i) a FLT3-inhibitor and (ii) SEL24/MEN1703.

5

17. The dosage form according to claim 16, wherein the FLT3-inhibitor is selected from the group consisting of Gilteritinib, Quizartinib, Midostaurin, and combinations thereof.